SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28thGlobeNewsWire • 09/14/21
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/12/21
SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021GlobeNewsWire • 07/28/21
SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian CancerGlobeNewsWire • 06/30/21
SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with OpdivoGlobeNewsWire • 06/24/21
SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/21
SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/23/21
SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17thGlobeNewsWire • 03/11/21
SLS Stock: 8 Things to Know About SELLAS Life Sciences as It Enjoys Reddit BumpInvestorPlace • 02/03/21
SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 MilestonesGlobeNewsWire • 01/14/21
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor IndicationsGlobeNewsWire • 12/21/20
SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 MillionGlobeNewsWire • 12/17/20
Why 3 Health Care Stocks Are Moving: Tv Therapeutics, Solid Biosciences, Sellas Life SciencesBenzinga • 12/11/20
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the BreastGlobeNewsWire • 12/11/20